INT354944

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.59
First Reported 2010
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 1
Total Number 7
Disease Relevance 1.18
Pain Relevance 0.59

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

plasma membrane (Shank3) cytoplasm (Shank3)
Shank3 (Mus musculus)
Pain Link Frequency Relevance Heat
nMDA receptor 14 92.84 High High
long-term potentiation 161 92.48 High High
antagonist 7 91.28 High High
nMDA receptor antagonist 7 75.76 Quite High
Glutamate receptor 28 73.80 Quite High
tetrodotoxin 7 73.76 Quite High
Neurobehavioral 28 70.92 Quite High
Pyramidal cell 21 64.96 Quite High
depression 49 5.00 Very Low Very Low Very Low
imagery 35 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Targeted Disruption 49 100.00 Very High Very High Very High
Syndrome 105 99.08 Very High Very High Very High
Schizophrenia 14 88.76 High High
Asperger Syndrome 7 82.08 Quite High
Autism 21 76.16 Quite High
Convulsion 7 51.84 Quite High
Congenital Anomalies 7 48.16 Quite Low
Mental Disorders 14 47.84 Quite Low
Cognitive Disorder 14 12.56 Low Low
Depression 49 5.00 Very Low Very Low Very Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The quantity of surface receptors controls synaptic strength [57-59]; therefore, reduction of both synaptic transmission and plasticity in the Shank3 heterozygotes would support a mechanism involving altered AMPA receptor trafficking.
Negative_regulation (reduction) of Shank3
1) Confidence 0.59 Published 2010 Journal Mol Autism Section Body Doc Link PMC3019144 Disease Relevance 0 Pain Relevance 0.23
In the present study, we summarize our results in mice with a disruption of the full-length Shank3 protein.
Negative_regulation (disruption) of Shank3
2) Confidence 0.59 Published 2010 Journal Mol Autism Section Body Doc Link PMC3019144 Disease Relevance 0 Pain Relevance 0
qPCR showed 50% reduction of full-length Shank3 mRNA in the heterozygotes and complete loss in knockouts (Figure 1B).
Negative_regulation (reduction) of Shank3
3) Confidence 0.43 Published 2010 Journal Mol Autism Section Body Doc Link PMC3019144 Disease Relevance 0.23 Pain Relevance 0
Careful characterization of mice with a disruption of Shank3 by targeting downstream exons common to the full-length, 22t and 32t forms will be of great interest, with the caveat that such targeting may produce dominant-negative shorter products truncated at the C-terminal that, depending on the exons targeted, may or may not be relevant to known clinical mutations.


Negative_regulation (disruption) of Shank3
4) Confidence 0.43 Published 2010 Journal Mol Autism Section Body Doc Link PMC3019144 Disease Relevance 0 Pain Relevance 0
In the current study, we characterized mice with a targeted disruption of Shank3 as a model for SHANK3-haploinsufficiency syndromes.
Negative_regulation (disruption) of Shank3 associated with targeted disruption and syndrome
5) Confidence 0.43 Published 2010 Journal Mol Autism Section Body Doc Link PMC3019144 Disease Relevance 0.51 Pain Relevance 0.04
These results indicate that there is a specific reduction in AMPA receptor-mediated basal transmission in the Shank3 heterozygous mice.
Negative_regulation (reduction) of Shank3
6) Confidence 0.38 Published 2010 Journal Mol Autism Section Body Doc Link PMC3019144 Disease Relevance 0 Pain Relevance 0.30
Haploinsufficiency of SHANK3 in neurodevelopmental syndromes
Negative_regulation (Haploinsufficiency) of SHANK3 associated with syndrome
7) Confidence 0.37 Published 2010 Journal Mol Autism Section Body Doc Link PMC3019144 Disease Relevance 0.44 Pain Relevance 0.03

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox